Compare Stocks: EOCN, FNCH, INTS, and KPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOCN Galmed Pharmaceuticals	$3.04 -3.8%	$4.41	$2.67 ▼ $12.32	$3.16M	0.66	158,670 shs	9,515 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
INTS Intensity Therapeutics	$3.52 -1.0%	$4.01	$3.10 ▼ $43.50	$11.54M	2.81	39,920 shs	20,233 shs
KPRX Kiora Pharmaceuticals	$2.46 -0.4%	$2.59	$1.76 ▼ $2.91	$10.87M	-0.22	177,331 shs	15,022 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOCN Galmed Pharmaceuticals	-31.15%	-31.15%	-31.15%	-23.08%	-73.13%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-36.63%
INTS Intensity Therapeutics	+7.25%	0.00%	-11.69%	-26.65%	-52.98%
KPRX Kiora Pharmaceuticals	-3.52%	-2.29%	-6.79%	-0.40%	-10.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EOCN Galmed Pharmaceuticals	$3.04 -3.8%	$4.41	$2.67 ▼ $12.32	$3.16M	0.66	158,670 shs	9,515 shs
FNCH Finch Therapeutics Group	$7.30	$7.30	$2.00 ▼ $16.10	$11.72M	1.18	5,025 shs	N/A
INTS Intensity Therapeutics	$3.52 -1.0%	$4.01	$3.10 ▼ $43.50	$11.54M	2.81	39,920 shs	20,233 shs
KPRX Kiora Pharmaceuticals	$2.46 -0.4%	$2.59	$1.76 ▼ $2.91	$10.87M	-0.22	177,331 shs	15,022 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EOCN Galmed Pharmaceuticals	-31.15%	-31.15%	-31.15%	-23.08%	-73.13%
FNCH Finch Therapeutics Group	0.00%	0.00%	0.00%	0.00%	-36.63%
INTS Intensity Therapeutics	+7.25%	0.00%	-11.69%	-26.65%	-52.98%
KPRX Kiora Pharmaceuticals	-3.52%	-2.29%	-6.79%	-0.40%	-10.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EOCN Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	99.15% Upside
KPRX Kiora Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest EOCN, FNCH, INTS, and KPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$5.00 ➝ $7.00
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	EOCN Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A
KPRX Kiora Pharmaceuticals	$16.02M	0.68	N/A	N/A	$4.38 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EOCN Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	N/A	N/A	N/A	-69.14%	-26.92%	N/A
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	11/6/2026 (Estimated)

Latest EOCN, FNCH, INTS, and KPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	KPRX Kiora Pharmaceuticals	-$0.38	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	INTS Intensity Therapeutics	-$0.94	N/A	N/A	N/A	N/A	N/A
9/2/2026	Q2 2026	EOCN Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EOCN Galmed Pharmaceuticals	N/A	4.16	4.16
FNCH Finch Therapeutics Group	N/A	3.87	3.87
INTS Intensity Therapeutics	0.01	5.00	5.00
KPRX Kiora Pharmaceuticals	N/A	8.97	8.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EOCN Galmed Pharmaceuticals	76.14%
FNCH Finch Therapeutics Group	21.77%
INTS Intensity Therapeutics	3.74%
KPRX Kiora Pharmaceuticals	76.97%

Insider Ownership

Company	Insider Ownership
EOCN Galmed Pharmaceuticals	19.80%
FNCH Finch Therapeutics Group	44.90%
INTS Intensity Therapeutics	7.60%
KPRX Kiora Pharmaceuticals	0.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EOCN Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
KPRX Kiora Pharmaceuticals	13	4.42 million	4.40 million	Not Optionable

EOCN, FNCH, INTS, and KPRX Headlines

Recent News About These Companies

Contrasting Jaguar Animal Health (NASDAQ:JAGX) & Kiora Pharmaceuticals (NASDAQ:KPRX)

October 7, 2026 | americanbankingnews.com

Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 1.2% - Time to Sell?

October 6, 2026 | americanbankingnews.com

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

September 8, 2026 | finance.yahoo.com

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

August 19, 2026 | newsfilecorp.comN

Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)

August 9, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 7, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

July 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

June 18, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan

June 11, 2026 | tipranks.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026 | newsfilecorp.comN

Kiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underway

April 15, 2026 | eurekalert.orgE

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

April 14, 2026 | newsfilecorp.comN

Kiora's KIO-301 Study in Retinitis Published, Phase 2 On

April 14, 2026 | miragenews.comM

Why did KPRX stock surge 17% pre-market today?

April 7, 2026 | msn.com

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finance.yahoo.com

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

April 7, 2026 | finanznachrichten.de

Kiora Pharmaceuticals Announces Chief Development Officer Resignation

April 5, 2026 | theglobeandmail.com

Kiora Pharmaceuticals Announces Management Team Changes

April 2, 2026 | newsfilecorp.comN

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

March 25, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EOCN, FNCH, INTS, and KPRX Company Descriptions

Galmed Pharmaceuticals NASDAQ:EOCN

$3.04 -0.12 (-3.80%)

As of 02:56 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Finch Therapeutics Group NASDAQ:FNCH

$7.30 0.00 (0.00%)

As of 10/13/2026

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Intensity Therapeutics NASDAQ:INTS

$3.52 -0.04 (-0.99%)

As of 03:22 PM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.46 -0.01 (-0.40%)

As of 03:14 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOCN, FNCH, INTS, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOCN, FNCH, INTS, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOCN, FNCH, INTS, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EOCN, FNCH, INTS, and KPRX Company Descriptions

Galmed Pharmaceuticals NASDAQ:EOCN

Finch Therapeutics Group NASDAQ:FNCH

Intensity Therapeutics NASDAQ:INTS

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EOCN, FNCH, INTS, and KPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EOCN, FNCH, INTS, and KPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EOCN, FNCH, INTS, and KPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EOCN, FNCH, INTS, and KPRX Company Descriptions

Galmed Pharmaceuticals NASDAQ:EOCN

Finch Therapeutics Group NASDAQ:FNCH

Intensity Therapeutics NASDAQ:INTS

Kiora Pharmaceuticals NASDAQ:KPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools